Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500 million RMB (~ USD 70 million). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.
Combination mechanisms for comprehensive metabolic control
Lead Asset – Zovigrutide (ZT002)
Feature
Detail
Generic Name
Zovigrutide (ZT002)
Class
GLP‑1 receptor agonist (GLP‑1RA)
Differentiation
Monthly administration (vs. weekly or daily competitors)
Indication
Weight management
Clinical Status
Phase III (HORIZON‑1 study) ongoing in China
Market Potential
World’s first once‑monthly GLP‑1 peptide if approved
Competitive Context
Challenges semaglutide (weekly), tirzepatide (weekly), and oral alternatives
Strategic Implications
Monthly Dosing Disruption:Once‑monthly GLP‑1 administration could fundamentally transform patient adherence and market dynamics, reducing injection burden and healthcare system costs associated with frequent clinic visits.
OrbiMed Validation:OrbiMed’s lead participation—a top‑tier global healthcare investor—signals strong confidence in QL Biopharma’s ultra‑long‑acting platform and Zovigrutide’s blockbuster potential.
China‑First Strategy:Phase III in China positions QL Biopharma for domestic market approval ahead of global competitors, with potential for out‑licensing ex‑China rights to multinational partners.
Metabolic Portfolio Depth: The ultra‑long‑acting + oral peptide + multi‑target technology stack supports pipeline expansion beyond GLP‑1 into GIP, glucagon, and combination therapies.
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III enrollment, regulatory pathways, and commercial potential for Zovigrutide. Actual results may differ due to risks including competitive weekly GLP‑1 launches, manufacturing scale‑up for monthly dosing formulations, and long‑term safety monitoring requirements.-Fineline Info & Tech
By Fineline Cube 